top of page

About Us

Finding key to every biological lock 

icon0-vector-129-01.jpg

bioLOCKEY Healthworks is a multidisciplinary innovation lab currently pioneering the next generation of Smart, Point of care diagnostics focused towards women health. We are dedicated to deliver self-use, safe, affordable and ultrasensitive rapid diagnostic tests to significantly advance health and health care practices. 

bioLOCKEY has developed a proprietary Nanobody discovery platform NANOdx. We have leveraged our knowledge of antigen-Nanobody molecular interactions to develop highly functional repertoires to surpass the diversity and functionality of the natural immune system. We have integrated these unique libraries within a yeast surface display system and optimized a high throughput methodology for the rapid discovery of Nanobodies to virtually any antigen/targets and their structure-guided optimization. We will also exploit NanoDx* to develop cell-based and virus-like particle antigen display methods for membrane-bound antigens.

​

Our vision is to bring in cutting edge, novel disruptive technologies in healthcare all the while keeping in mind affordability, accuracy and potency

icon0-vector-129-01.jpg
abstract-swirls

Meet the Team

bioLOCKEY Healthworks is a collaboration between  Scientists, chemists and bio-engineers. This collaboration provides the opportunity for scientific theory to drive biotechnology advancement for optimal clinical outcomes via bio-engineered systems

  • Previous affiliation: MRC, UK; Stanford Bioengineering, USA; Max-Planck Institute,Germany

  • 15 years of research experience in Small molecule therapeutics and drug Discovery

  • Expertise in Bioengineering, Molecular Imaging, Biological screening & Validation

  • Previous Affiliation: UCSF, CA, USA; Max-Planck Institute, Germany

  • 20 years of research experience in Structural Biochemistry, crystallography

  • Expertise in Protein engineering, Nanobody based biologics discovery and development

  • Founder Cytokinetics Inc., MyoKardia Inc., Kainomyx Inc. & Cyntegron Therapeutics

  • Developed first FDA approved drug for cardiomyopathies with MyoKardia Inc.

  • Over 50 years of research experience in drug development

  • Founding Dean-instem, India

  • Founder/CEO- CCAMP, India

  • Over 40 years of research experience in Structural Biology, Biochemistry, Drug discovery

  • LinkedIn
  • LinkedIn
  • Twitter
  • LinkedIn
  • Twitter
  • LinkedIn
  • Twitter

  • Education: BTech/ MTech Biotechnology

  •  Experience in Development and Optimization of vertical Flow Technology,  In-vitro diagnostic tests

​

  • Previous Affiliation: Postdoctoral fellow-instem, Skanda Lifesciences/ Enzene Biosciences/ Jubilant Biosciences

  • Over 10 years of research experience in Antibody engineering, Cell-based biosimilars screening

  • LinkedIn
  • LinkedIn

Our Core Values

bottom of page